Beren Therapeutics Presents Six Data Sets on Adrabetadex at 2026 APMRF Conference
Event summary
- Beren Therapeutics will present six posters on adrabetadex at the 2026 APMRF Conference, May 30–June 2.
- Posters highlight clinical and preclinical data on adrabetadex for infantile-onset Niemann-Pick disease, type C (I-NPC).
- CEO Jason Camm to participate in a fireside chat with APMRF director Sean Kassen on May 31.
- FDA granted adrabetadex Breakthrough Therapy Designation in 2025; NDA accepted for Priority Review with PDUFA target date of November 17, 2026.
The big picture
Beren Therapeutics is positioning adrabetadex as a potential cornerstone therapy for I-NPC, leveraging data from clinical studies and Expanded Access Programs. The company's focus on early treatment initiation aligns with broader industry trends emphasizing proactive intervention in rare neurodegenerative diseases. The strategic emphasis on combination therapies could expand adrabetadex's addressable market, particularly if preclinical data on mechanistic compatibility translates into clinical benefits.
What we're watching
- Regulatory Timeline
- Whether the FDA will meet the November 17, 2026, PDUFA target action date for adrabetadex.
- Clinical Efficacy
- How the data on early treatment and long-term outcomes will influence adrabetadex's market positioning.
- Combination Therapy
- The pace at which Beren can establish adrabetadex as a foundational therapy alongside existing NPC treatments.
Related topics